ViiV presents detailed Phase III primary endpoint data for two-drug HIV regimen

ViiV Healthcare Ltd. (Brentford, U.K.) presented pooled additional data from a pair of Phase III trials in HIV-1 infected patients showing that its two-drug regimen of dolutegravir and lamivudine led to HIV-1 RNA levels of less than 50 copies/mL at week 48, the primary endpoint, in 91% of patients vs. 93% of patients who received Tivicay dolutegravir plus Truvada emtricitabine/tenofovir. Data were presented at the International AIDS Conference in Amsterdam.

The company said 1% or fewer patients had virologic failure across all study arms, and no patient who experienced virologic failure developed treatment-emergent resistance. Treatment-related adverse events were less frequent in patients receiving dolutegravir/lamivudine compared with the three-drug regimen...